Associations - FGFR mutation

FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	erdafitinib Sensitive: C2 – Inclusion Criteria	erdafitinib Sensitive: C2 – Inclusion Criteria
FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	FGFR inhibitor Sensitive: C3 – Early Trials	FGFR inhibitor Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Solid Tumor Solid Tumor	FGFR mutation FGFR mutation	Solid Tumor Solid Tumor	ICP-192 Sensitive: C3 – Early Trials	ICP-192 Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Breast Cancer Breast Cancer	FGFR mutation FGFR mutation	Breast Cancer Breast Cancer	E7090 Sensitive: D – Preclinical	E7090 Sensitive: D – Preclinical